WJ-39 is an orally active aldose reductase (AR) inhibitor that ameliorates renal lesions in diabetic nephropathy through activation of Nrf2 signaling, and may be used to ameliorate renal insufficiency and fibrosis.WJ-39 inhibits oxidative stress and inhibits the activation of the inflammatory vesicle of the oligomerization structural domain-like receptor family, pyrin structural domain 3 (NLRP3).
Marketplace OffersShowing from 1 suppliers
Supplier
TargetMolSC
Pack Size
Estimated Lead Time
1-3 days
Purity
99.74%
$ 70.00
1
You cannot determine which compound library is the best fit for your project? Do you need a custom solution? AnyMol is always ready to help you.